Acumen Pharmaceuticals (ABOS) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, gaining 12.8% versus a gain of 11.7%. Over five years, ABOS leads with a -84.5% price change compared with -97.8% for DTIL. Precision BioSciences is the larger company by market cap ($177.5 million vs $151.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | DTIL |
|---|---|---|
| Share price | $2.10 | $6.43 |
| Market cap | $151.87M | $177.48M |
| 1-day change | 0.00% | +2.88% |
| YTD return | -0.47% | +54.57% |
| 1-year return | +11.70% | +12.81% |
| 5-year return | -84.50% | -97.81% |
| EPS (TTM) | $-1.64 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $9.62 |
| 52-week low | $1.50 | $3.53 |
| Distance from 52-week high | -41.67% | -33.16% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +261.90% | +357.23% |
| Average volume | 439.10K | 287.13K |
| Shares outstanding | 72.32M | 27.60M |
| Employees | 60 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
ABOS vs DTIL FAQ
Which is bigger, Acumen Pharmaceuticals or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $177.48M compared with $151.87M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or DTIL?
DTIL returned +12.81% over the past 12 months, compared with +11.70% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Precision BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.